NASDAQ:VRAX Virax Biolabs Group (VRAX) Stock Price, News & Analysis $0.57 -0.01 (-0.89%) As of 09:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Virax Biolabs Group Stock (NASDAQ:VRAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Virax Biolabs Group alerts:Sign Up Key Stats Today's Range$0.56▼$0.5850-Day Range$0.57▼$1.1152-Week Range$0.56▼$4.44Volume20,803 shsAverage Volume329,738 shsMarket Capitalization$2.46 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company Overview Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. Read More Virax Biolabs Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreVRAX MarketRank™: Virax Biolabs Group scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVirax Biolabs Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVirax Biolabs Group has received no research coverage in the past 90 days.Read more about Virax Biolabs Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioVirax Biolabs Group has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Virax Biolabs Group's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.05% of the float of Virax Biolabs Group has been sold short.Short Interest Ratio / Days to CoverVirax Biolabs Group has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virax Biolabs Group has recently increased by 176.35%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVirax Biolabs Group does not currently pay a dividend.Dividend GrowthVirax Biolabs Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.05% of the float of Virax Biolabs Group has been sold short.Short Interest Ratio / Days to CoverVirax Biolabs Group has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virax Biolabs Group has recently increased by 176.35%, indicating that investor sentiment is decreasing significantly. News and Social Media1.5 / 5News Sentiment-0.23 News SentimentVirax Biolabs Group has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Virax Biolabs Group this week, compared to 0 articles on an average week.Search Interest1 people have searched for VRAX on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Virax Biolabs Group insiders have not sold or bought any company stock.Percentage Held by Insiders45.10% of the stock of Virax Biolabs Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.61% of the stock of Virax Biolabs Group is held by institutions.Read more about Virax Biolabs Group's insider trading history. Receive VRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virax Biolabs Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRAX Stock News HeadlinesVirax Biolabs (VRAX) Falls 18% on Lack of LeadsAugust 27, 2025 | insidermonkey.comVirax BioLabs Group Limited: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberAugust 27, 2025 | finanznachrichten.deWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.September 3 at 2:00 AM | Porter & Company (Ad)Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberAugust 26, 2025 | prnewswire.comVirax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial StrategyJuly 29, 2025 | prnewswire.comVirax Biolabs Group Limited (VRAX) Latest Stock News & Headlines ...July 22, 2025 | finance.yahoo.comVirax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyJuly 20, 2025 | finanznachrichten.deVirax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyJuly 18, 2025 | prnewswire.comSee More Headlines VRAX Stock Analysis - Frequently Asked Questions How have VRAX shares performed this year? Virax Biolabs Group's stock was trading at $2.25 on January 1st, 2025. Since then, VRAX shares have decreased by 74.6% and is now trading at $0.5711. When did Virax Biolabs Group's stock split? Virax Biolabs Group shares reverse split on Monday, December 18th 2023.The 1-10 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virax Biolabs Group IPO? Virax Biolabs Group (VRAX) raised $7 million in an initial public offering on Thursday, July 21st 2022. The company issued 1,400,000 shares at a price of $5.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Virax Biolabs Group? Shares of VRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virax Biolabs Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virax Biolabs Group investors own include Plug Power (PLUG), GeoVax Labs (GOVX), Fortress Biotech (FBIO), KALA BIO (KALA), Comtech Telecommunications (CMTL), FuelCell Energy (FCEL) and Lipocine (LPCN). Company Calendar Today9/03/2025Next Earnings (Estimated)10/01/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRAX CIK1885827 Webviraxbiolabs.com Phone44-0-20-7788-7414FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Virax Biolabs Group$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+425.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio7.27 Quick Ratio7.13 Sales & Book Value Annual Sales$10 thousand Price / Sales247.86 Cash FlowN/A Price / Cash FlowN/A Book Value$1.26 per share Price / Book0.45Miscellaneous Outstanding Shares4,340,000Free Float2,384,000Market Cap$2.48 million OptionableNot Optionable Beta1.64 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:VRAX) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.